Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 4/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2514355 | 0.92 | NR1H2 (0.39) | HTRA1UCHL1CYP1A2POLBCYP3A4 | |
| SCHEMBL2672129 | 0.87 | AGTR2 (0.37) | AGTR2 | |
| SCHEMBL12479562 | 0.87 | FKBP1A (0.41) | POLBJAK2JAK1CETP | |
| SCHEMBL15799372 | 0.82 | BIRC2 (0.41) | CYP3A4CYP2C19 | |
| SCHEMBL4691626 | 0.80 | MEN1 (0.33) | UCHL1CYP1A2CYP2C19NR1H2NR1H3 | |
| SCHEMBL4492695 | 0.77 | F10 (0.49) | — | |
| SCHEMBL3865888 | 0.77 | MEN1 (0.33) | HTRA1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1393390 | 0.77 | CASP1 (0.38) | HTRA1UCHL1JAK2JAK1AGTR2 | |
| SCHEMBL13074008 | 0.74 | HTRA1 (0.41) | HTRA1UCHL1CYP1A2POLBCYP3A4 | |
| SCHEMBL18606142 | 0.74 | BRD4 (0.45) | HTRA1UCHL1CYP1A2POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1748980-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005115977-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | HTRA1 3142/4885UCHL1 1871/4885CYP1A2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.